NEWS
Recently, the innovation and transformation of China's biomedical industry chainCBIITAThe enlarged executive directorate meeting of the consortium was held on '2023The opening ceremony of the First Yangtze River Delta Biopharmaceutical Industry Conference and the 4th China International Summit on Innovation and Transformation of the Biopharmaceutical Industry Chain was successfully held in Hangzhou before its commencement.
At the meeting, Frost & SullivanFrost & SullivanDr. Wang Xin, Global Partner and Chairman of Frost & Sullivan Greater China, has been appointed asCBIITAExecutive Director of the Consortium, Academician of the Chinese Academy of Sciences, Deputy Chief Designer of National Major New Drug Creation Technologies, former President of the Shanghai Association for Science and TechnologyCBIITAChairman of the Consortium, Editor-in-Chief of 'Advances in Pharmacy', Yangtze River Delta Data-Driven Innovation Biopharmaceutical Industry Chain AllianceYBDIAAcademician Chen Kaixian, honorary chairman of the board, presented a letter of appointment to Dr. Wang Xin.
(Dr. Wang Xin, left); Academician Chen Kaixian, right)
The council meeting isCBIITAAt the first executive council meeting of the consortium after its joining the China Industry-University-Research Cooperation Promotion Association, there were President Wang Jianhua of the China Industry-University-Research Cooperation Promotion Association, Executive Vice President Lei Zhaozi, former Director of the Department of Science, Education and Information of the Ministry of Education,CBIITAAcademician Chen Kaixian, President of the Consortium; Du Guanhua, Secretary of the Party Committee of the Chinese Pharmacological Society and former Vice President of the Chinese Academy of Medical Sciences; Pan Guangcheng, Senior President of the China Chemical Pharmaceutical Industry Association, and other vice presidents, executive directors, and industry elites, experts, and scholars80People attended the meeting. At this meeting,CBIITAThe important decisions and cooperation agendas of the consortium were actively discussed, injecting new vitality and innovative momentum into the global biopharmaceutical field. A series of important cooperation and strategic decisions reached at the meeting will have a profound impact in the future.
Academician of the Chinese Academy of Sciences, Deputy Chief Designer of National Major New Drug Creation TechnologiesCBIITAChairman of the Consortium Academician Chen Kaixian
Academician of the Chinese Academy of Sciences, Deputy Chief Designer of National Major New Drug Creation TechnologiesCBIITAAcademician Chen Kaixian, President of the Consortium, delivered an important speech. He profoundly analyzed the current development trends in the biomedical field and emphasized that global cooperation is key to promoting biomedical innovation.CBIITAThe consortium will play a bridging and linking role, facilitating the sharing of advantageous resources among different regions.
Academician Chen Kaixian especially affirmedCBIITAThe consortium's strategic decision to join the China Industry-University-Research Cooperation Promotion Association is considered an important step in promoting in-depth industry-university-research cooperation. This decision will bring broader resource support to the consortium and drive deeper integration of innovation within the industrial chain.
Global Partner and Chairman of Frost & Sullivan Greater China Region Dr. Wang Xin
Dr. Wang Xin stated that he is honored to join the China Biomedical Industry Chain Innovation and Transformation Consortium as a standing council member. Frost & Sullivan has always regarded the life sciences as one of its core areas of focus. With a global perspective, it is committed to providing full lifecycle services for enterprises in the life sciences during the investment and financing stages, helping clients accelerate their growth and achieve leading benchmarks in industry growth, innovation, and technology. Over the past nearly thirty years since entering the Chinese market, Frost & Sullivan has participated in mentoring and has witnessed the growth of hundreds of enterprises in the life sciences sector.
The biopharmaceutical industry is an important part of the bioeconomy, one of the most dynamic and promising high-tech industries in the world today, and also one of China's national strategic emerging industries. It holds significant importance and broad development prospects.
In future development, Frost & Sullivan will firmly leverage its global brand value, relying on its profound professional expertise and outstanding service standards to further increase its support for the biopharmaceutical industry. "We will be committed to strengthening industry research, andCBIITAThe consortium, together, aims to cultivate more professionals to promote the healthy, sustainable, and high-quality development of China's biopharmaceutical industry, make greater contributions to people's health and economic development, and jointly create a better future. "Dr. Wang Xin said.
Attachment:
CBIITAList of additional scientific advisors:
Zhang Xueji Academician of the American Institute for Medical and Biological Engineering, Foreign Member of the Russian Academy of Engineering, Academician of the European Academy of Sciences, Fellow of the Royal Society of Chemistry in the UK, Standing Committee Member of the Party Committee and Vice President of Shenzhen University
Wei Qiming American College of Cardiology FellowFACCMember of the American Thoracic SocietyFCCPChief Scientist of Zhongguancun Medical Innovation Center, Executive Chairman of Zhongguancun International Academician Alliance
Wu Xifeng Dean of the School of Public Health at Zhejiang University, Changjiang Scholar, National Distinguished Expert, Dean of the National Research Institute of Health Care Big Data, and Deputy Dean of the Second Affiliated Hospital of Zhejiang University School of Medicine
CBIITAList of additional vice-chairmen:
Zhang Dan Foreign Academician of the Russian Academy of Engineering, co-founder of Puxin Biotechnology&Co-Founder and Chief Strategy Officer of Kunling (formerlyCBIITAJoint Venture Scientific Advisor)
Cao Xiaochun Co-founder and President of Hangzhou TagMed (formerlyCBIITAExecutive Director of the Consortium (represented by the relying unit)
CBIITAList of newly elected executive directors:
willow red Researcher at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Deputy Director of the Academic Committee, formerCBIITAJoint Venture Council
king listen Global Partner and Chairman of Frost & Sullivan Greater China Region
easy hua Director and General Manager of SDIC China Merchants Investment Management Co., Ltd.
CBIITAList of additional Deputy Secretaries-General for election:
Yang Changyong Vice General Manager of Shanghai Shengdi Pharmaceutical Co., Ltd., Hengrui Medicine
Cao Beili Vice President of Hualing Medicine
Zhang Hongqiao Vice President of Tiger Medicine
Zou Zijian Assistant to the Chairman of Suzhou Yasheng Pharmaceutical Co., Ltd.&CEODeputy Director of the Office
Qiang Yongliang Representative of Gemaribo China
